Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Ambrx Biopharma Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/12/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/12/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/12/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
10/12/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
10/12/2023 8-K Quarterly results
10/10/2023 8-K Quarterly results
10/10/2023 SC 13G HOPU Reunion Co Ltd reports a 8.9% stake in Ambrx Biopharma Inc.
10/06/2023 8-K Resignation/termination of a director
08/25/2023 8-K Other Events  Interactive Data
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/28/2023 SC 13D/A Darwin Global Management, Ltd. reports a 27.5% stake in Ambrx Biopharma Inc.
06/28/2023 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Ambrx Announces Closing of $75 Million Market Priced Registered Offering SAN DIEGO"
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/25/2023 SC 13D/A Darwin Global Management, Ltd. reports a 20.5% stake in Ambrx Biopharma Inc.
05/25/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Opinion of Maples & Calder (Hong Kong) LLP",
"Securities Purchase Agreement, by and between Ambrx Biopharma Inc. and the Purchasers",
"Ambrx Announces $75 Million Market Priced Registered Offering"
05/25/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/18/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/18/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Ambrx Appoints Stephen Glover as Chairman of its Board of Directors"
05/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment to Executive Employment Agreement by and between the Company and Daniel J. O’Connor",
"Amendment to Executive Employment Agreement by and between the Company and Daniel J. O’Connor"
05/16/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
05/03/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/27/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
04/18/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/16/2023 CERT Form CERT - Certification by an exchange approving securities for listing:
03/16/2023 25 Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities:
03/16/2023 SC 13G D. E. SHAW & CO, L.P. reports a 8.2% stake in Ambrx Biopharma Inc.
03/16/2023 8-A12B/A Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]
03/13/2023 SC 13G/A Cormorant Asset Management, LP reports a 17.7% stake in Ambrx Biopharma Inc.
03/13/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Ambrx Raises $78 Million and Completes its ATM Program"
03/08/2023 SC 13D Darwin Global Management, Ltd. reports a 26.4% stake in Ambrx Biopharma Inc.
03/06/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Ambrx to Commence Trading on Nasdaq"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy